EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX:AIS) reports that its low-dose testosterone ATD™ gel for the treatment of FSD (female sexual dysfunction) has had the regulatory pathway for approval clarified by the U.S. Food and Drug Administration (FDA). “Clarification of a regulatory pathway from the FDA for testosterone ATD™ gel is very important news that reopens the prospects for approval in the U.S. as well as in Europe, each large potential markets, after several years of little regulatory progress. It also demonstrates the approvability of our core gel platform while emphasizing the flexibility of our technology in the key therapeutic area of women’s health,” commented Jack E. Stover, President & CEO.
